List view / Grid view

infliximab (Biosimilar: Remsima)


Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases.

Infliximab was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Crohn’s diseaseulcerative colitispsoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis. It is used off-label outside its FDA approval for Behçet’s disease and other conditions. Infliximab is administered by intravenous infusion, typically at six- to eight-week intervals. It cannot be given by mouth because the digestive system would destroy the drug.

Infliximab is an artificial antibody, and works by binding to TNF-α. TNF-α is a chemical messenger (cytokine) and a key part of the autoimmune reaction. In rheumatoid arthritis, infliximab seems to work by preventing TNF-α from binding to its receptor in the cell. Infliximab biosimilars have been approved in the EU (2013), Japan (2014), and USA (2016).